#55 🧬 Perfecting Nature’s Blueprint
#54 🌿 The Beauty of Nature’s Design
#53 🧪 The Experiment That Started It All
#52 🥊 Positioned to Win: Why Cytonics Stands Out in the 2025 Biotech Landscape
#51 🥋 When Injury Meets Innovation: Rener Gracie’s Journey to Cytonics
#50🔊Listen To Our CEO Describe Our Science In 40 Seconds
#49 🦈 When a Shark Asks the Right Questions
Cytonics Announces Initiation Of First-In-Human Phase 1 Clinical Study For CYT-108 In Patients Suffering From Osteoarthritis Of The Knee
April 22, 202586ViewsRead more
Cytonics Announces Completion Of Enrollment For Phase 1 Clinical Study Evaluating CYT-108, A Novel Recombinant Protease Inhibitor, In Patients Suffering From Osteoarthritis Of The Knee
April 22, 202577ViewsRead more
Cytonics Announces Successful Completion of Phase 1 Study for First Nine Patients in CYT-108 Clinical Trial
April 22, 202553ViewsRead more
Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development
April 22, 202582ViewsRead more
#48 🎉Major Milestone: Last Patient Completes Phase 1 Clinical Trial
March 31, 202591ViewsRead more
#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development
March 25, 202545ViewsRead more
#46 📢 Critical Patent Issuance Protecting Lead Drug Candidate
#45 🚨 Major Phase 1 Study Milestone Achieved!
January 17, 202526ViewsRead more
